Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4509470 | 0.86 | LMNA (0.36) | LMNACA12CA1CA2CA3 | |
| SCHEMBL12052217 | 0.83 | LMNA (0.40) | LMNACA12CA1CA2CA3 | |
| SCHEMBL5045379 | 0.83 | TP53 (0.31) | — | |
| SCHEMBL10164152 | 0.73 | LMNA (0.48) | LMNACA12CA1CA2CA3 | |
| SCHEMBL28033505 | 0.70 | LMNA (0.41) | LMNACA12CA1CA2CA3 | |
| SCHEMBL2684262 | 0.70 | LMNA (0.50) | LMNACA12CA1CA2CA3 | |
| SCHEMBL10078330 | 0.70 | LMNA (0.50) | LMNACA12CA1CA2CA3 | |
| SCHEMBL433367 | 0.69 | LMNA (0.42) | LMNACA12CA1CA2CA3 | |
| SCHEMBL433366 | 0.69 | LMNA (0.42) | LMNACA12CA1CA2CA3 | |
| SCHEMBL8236666 | 0.69 | LMNA (0.42) | LMNACA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020052545-A1 | METHOD FOR PREPARING BRIVARACETAM AND INTERMEDIATES THEREOF | 上海宣泰医药科技有限公司 | 2020-03-19 | — | — | WO | disclosed |
| WO-2020051796-A1 | PREPARATION METHOD FOR BRIVARACETAM AND INTERMEDIATE THEREOF | 上海宣泰医药科技有限公司 | 2020-03-19 | — | — | WO | disclosed |
| EP-1993998-B1 | 3-CARBOXY- 2-OXO-1 -PYRROLIDINE DERIVATIVES AND THEIR USES | UCB PHARMA SA (BE) | 2013-08-21 | — | — | EP | disclosed |
| EP-1993998-B1 | 3-CARBOXY- 2-OXO-1 -PYRROLIDINE DERIVATIVES AND THEIR USES | UCB PHARMA SA (BE) | 2013-08-21 | — | — | EP | disclosed |
| US-20120021469-A1 | AMIDASES AND METHODS OF THEIR USE | CODEXIS, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120021469-A1 | AMIDASES AND METHODS OF THEIR USE | CODEXIS, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-8076493-B2 | 3-carboxy-2-oxo-1-pyrrolidine derivatives and their uses | UCB PHARMA, S.A. (BE) | 2011-12-13 | — | — | US | disclosed |
| US-8076493-B2 | 3-carboxy-2-oxo-1-pyrrolidine derivatives and their uses | UCB PHARMA, S.A. (BE) | 2011-12-13 | — | — | US | disclosed |
| US-8076493-B2 | 3-carboxy-2-oxo-1-pyrrolidine derivatives and their uses | UCB PHARMA, S.A. (BE) | 2011-12-13 | — | — | US | disclosed |
| WO-2010111622-A2 | AMIDASES AND METHODS OF THEIR USE | CODEXIS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| US-20090012313-A1 | 3-Carboxy-2-Oxo-1-Pyrrolidine Derivatives and Their Uses | UCB PHARMA, S.A. (BE) | 2009-01-08 | — | — | US | disclosed |
| US-20090012313-A1 | 3-Carboxy-2-Oxo-1-Pyrrolidine Derivatives and Their Uses | UCB PHARMA, S.A. (BE) | 2009-01-08 | — | — | US | disclosed |
| US-20090012313-A1 | 3-Carboxy-2-Oxo-1-Pyrrolidine Derivatives and Their Uses | UCB PHARMA, S.A. (BE) | 2009-01-08 | — | — | US | disclosed |
| WO-2007065634-A1 | 3-CARBOXY- 2-OXO-1 -PYRROLIDINE DERIVATIVES AND THEIR USES | UCB PHARMA, S.A. (BE) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021469-A1 | AMIDASES AND METHODS OF THEIR USE | ANPEP, DNPEP, NAAA | LMNA 2107/4885CA12 2038/4885CA1 1624/4885 |
| US-20090012313-A1 | 3-Carboxy-2-Oxo-1-Pyrrolidine Derivatives and Their Uses | ALDH18A1, PYCR1, OPRD1 | LMNA 4658/4885CA12 1665/4885CA1 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.